Tissue and plasma expression of the angiogenic peptide adrenomedullin in breast cancer
2003

Adrenomedullin in Breast Cancer

Sample size: 53 publication 10 minutes Evidence: moderate

Author Information

Author(s): Oehler M K, Fischer D C, Orlowska-Volk M, Herrle F, Kieback D G, Rees M C P, Bicknell R

Primary Institution: Cancer Research UK, University of Oxford

Hypothesis

Does adrenomedullin expression in breast cancer tissues correlate with clinical outcomes?

Conclusion

Adrenomedullin is widely expressed in breast malignancies and its levels in plasma may reflect tumor size and lymph node involvement.

Supporting Evidence

  • 82% of breast cancer samples showed moderate to strong adrenomedullin staining.
  • Patients with lymph node metastasis had higher adrenomedullin expression.
  • Plasma adrenomedullin levels were significantly higher in patients with larger tumors.

Takeaway

This study looked at a substance called adrenomedullin in breast cancer and found that higher levels might mean the cancer is more serious.

Methodology

The study examined adrenomedullin expression in breast cancer tissues and plasma samples from patients and healthy controls using immunohistochemistry and radioimmunoassay.

Potential Biases

Potential bias in patient selection and the retrospective nature of the study.

Limitations

The study had a limited sample size and did not find correlations with all clinicopathological features.

Participant Demographics

33 breast cancer patients and 18 healthy female controls.

Statistical Information

P-Value

0.030

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6601397

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication